ABBV Jan 2024 135.000 put
| Previous close | 14.66 |
| Open | 13.25 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 135.00 |
| Expiry date | 2024-01-19 |
| Day's range | 13.25 - 14.66 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- PR Newswire
CHMP Recommends European Commission Approval of Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderate to Severe Ulcerative Colitis
AbbVie (NYSE: ABBV) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of upadacitinib (RINVOQ®, 45 mg [induction dose] and 15 mg and 30 mg [maintenance dose]) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.*
- Zacks
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
- Zacks
Pharma Stock Roundup: FDA Nod to PFE COVID Jab for Age 5-11 & LLY's Tirzepatide
FDA grants emergency approval to Pfizer's COVID-19 vaccine for use in children 5- to 11-year old and approves Lilly's (LLY) novel diabetes treatment, Mounjaro (tirzepatide).
